Determining Tumor Biological Biotype - Immunohistochemistry (IHC) Interpretation and Consultation (3 Markers)

A systematic interpretive consultation package is provided based on the analysis and integration of results from three pivotal immunohistochemical (IHC) markers selected based on the clinical evidence for the specific tumor type. The package includes an assessment of the individual expression of each marker, followed by analysis of possible triplet patterns (e.g., +/+/+, +/+/–, +/–/–, etc.) according to recognized diagnostic or classification algorithms (e.g., classifying breast cancer into Luminal A, Luminal B, HER2-enriched, or Triple-negative based on ER, PR, and HER2). The pathologist interprets the results to determine the tumor's triplet "biophenotype" and issue initial treatment recommendations based on this classification.